Key result
The barley unique epitope DQ2.5-hor-3 elicited a T-cell response in the majority of celiac disease patients, characterized by clonal expansion and preferential, public TCR V-gene usage.
Why the study?
Barley is a prominent source of gluten, but knowledge regarding T-cell responses elicited by barley in celiac disease is scarce.
Biased and public TCRs underpin the T-cell response to the immunodominant barley gluten epitope in celiac disease, suggesting these T cells are potential diagnostic and therapeutic targets.
May guide celiac diagnostics and therapies via public TCRs; hypothesis-generating from Level 5 data, needs human validation.
T-cell responses to dietary gluten proteins of wheat, barley, and rye when deamidated gluten epitopes are presented by certain disease-associated HLA-DQ allotypes. About 90% of the CeD patients express HLA-DQ2.5. In such patients, five gluten epitopes dominate the anti-gluten T-cell response; two epitopes unique to wheat, two epitopes present in wheat, barley, and rye and one epitope unique to barley. Despite presence of barley in commonly consumed food and beverages and hence being a prominent source of gluten, knowledge about T-cell responses elicited by barley in CeD is scarce. Therefore, in this study, we explored T-cell response toward the barley unique epitope DQ2.5-hor-3 (PIPEQPQPY) by undertaking HLA-DQ:gluten peptide tetramer staining, single-cell T-cell receptor (TCR) αβ sequencing, T-cell cloning, and T-cell proliferation studies. We demonstrate that majority of the CeD patients generate T-cell response to DQ2.5-hor-3, and this response is characterized by clonal expansion, preferential TCR V-gene usage and public TCR features thus echoing findings previously made for wheat gluten epitopes. The knowledge that biased and public TCRs underpin the T-cell response to all the immunodominant gluten epitopes in CeD suggests that such T cells are promising diagnostic and therapeutic targets.
No takes yet. Share an insight, caveat, or question.
Dahal‐Koirala et al. (2019) studied Celiac disease. Barley unique epitope DQ2.5-hor-3 was evaluated on T-cell response toward the barley unique epitope DQ2.5-hor-3. The barley unique epitope DQ2.5-hor-3 elicited a T-cell response in the majority of celiac disease patients, characterized by clonal expansion and preferential, public TCR V-gene usage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: